PE20200700A1 - Compuestos macrociclicos y usos de los mismos - Google Patents
Compuestos macrociclicos y usos de los mismosInfo
- Publication number
- PE20200700A1 PE20200700A1 PE2020000127A PE2020000127A PE20200700A1 PE 20200700 A1 PE20200700 A1 PE 20200700A1 PE 2020000127 A PE2020000127 A PE 2020000127A PE 2020000127 A PE2020000127 A PE 2020000127A PE 20200700 A1 PE20200700 A1 PE 20200700A1
- Authority
- PE
- Peru
- Prior art keywords
- independently
- compound
- deuterium
- fluoro
- chloro
- Prior art date
Links
- 150000002678 macrocyclic compounds Chemical class 0.000 title abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 abstract 2
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052805 deuterium Inorganic materials 0.000 abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 abstract 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000001246 bromo group Chemical group Br* 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Abstract
Referida a un compuesto macrociclico de formula (I), en donde X1 y X2 son, independientemente, -CR6 R7-, S, entre otros; R1 es H, deuterio, C1-C6 alquilo, entre otros; cada R2 y R3 es, independientemente, H, deuterio, C1-C6 alquilo, entre otros; R4 es H, entre otros; R5 es H o -NR6R7; cada R6, R7 y R8 se seleccionan cada uno, independientemente, del grupo que consiste en H, C2-C6 alquenilo, entre otros; R9 es H, fluoro, cloro, entre otros; R10 es H, fluoro, cloro o bromo y n es 1 o 2. Dicho compuesto inhibe las cinasas SRC y MET y/o CSF1R, siendo util en el tratamiento de cancer. Tambien se refiere a composiciones farmaceuticas que contiene dicho compuesto
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762538193P | 2017-07-28 | 2017-07-28 | |
| US201862700990P | 2018-07-20 | 2018-07-20 | |
| PCT/US2018/043817 WO2019023417A1 (en) | 2017-07-28 | 2018-07-26 | MACROCYCLIC COMPOUNDS AND USES THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20200700A1 true PE20200700A1 (es) | 2020-06-23 |
Family
ID=65039935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020000127A PE20200700A1 (es) | 2017-07-28 | 2018-07-26 | Compuestos macrociclicos y usos de los mismos |
Country Status (29)
| Country | Link |
|---|---|
| US (4) | US11286264B2 (es) |
| EP (1) | EP3658148B1 (es) |
| JP (2) | JP7224334B2 (es) |
| KR (1) | KR102645316B1 (es) |
| CN (1) | CN111182903A (es) |
| AU (1) | AU2018306328B2 (es) |
| BR (1) | BR112020001695A2 (es) |
| CA (1) | CA3069232A1 (es) |
| CL (1) | CL2020000169A1 (es) |
| CO (1) | CO2020000633A2 (es) |
| DK (1) | DK3658148T3 (es) |
| ES (1) | ES2986593T3 (es) |
| FI (1) | FI3658148T3 (es) |
| HR (1) | HRP20241197T1 (es) |
| IL (1) | IL271964B2 (es) |
| LT (1) | LT3658148T (es) |
| MY (1) | MY201925A (es) |
| PE (1) | PE20200700A1 (es) |
| PH (1) | PH12020500033A1 (es) |
| PL (1) | PL3658148T3 (es) |
| PT (1) | PT3658148T (es) |
| RS (1) | RS65884B1 (es) |
| SA (1) | SA520411108B1 (es) |
| SG (1) | SG11202000356VA (es) |
| SI (1) | SI3658148T1 (es) |
| SM (1) | SMT202400343T1 (es) |
| TW (1) | TWI818917B (es) |
| UA (1) | UA126158C2 (es) |
| WO (1) | WO2019023417A1 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201892241A1 (ru) | 2014-01-24 | 2019-02-28 | ТиПи ТЕРАПЬЮТИКС, ИНК. | Диарильные макроциклы в качестве модуляторов протеинкиназ |
| CA2989327A1 (en) | 2015-07-02 | 2017-01-05 | Tp Therapeutics, Inc. | Chiral diaryl macrocycles as modulators of protein kinases |
| PT3733187T (pt) | 2015-07-21 | 2024-11-08 | Turning Point Therapeutics Inc | Macrociclo de diarilo quiral e utilização do mesmo no tratamento do cancro |
| CA3031100A1 (en) | 2016-07-28 | 2018-02-01 | Tp Therapeutics, Inc. | Macrocycle kinase inhibitors |
| TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| MY201925A (en) | 2017-07-28 | 2024-03-23 | Turning Point Therapeutics Inc | Macrocyclic compounds and uses thereof |
| CN109516999B (zh) * | 2017-11-01 | 2021-08-17 | 郑州泰基鸿诺医药股份有限公司 | 用作蛋白质激酶调节剂的化合物及其应用 |
| PT3728271T (pt) | 2017-12-19 | 2022-10-06 | Turning Point Therapeutics Inc | Compostos macrocíclicos para tratar doenças |
| PL3786167T3 (pl) | 2018-04-25 | 2024-11-25 | Primegene (Beijing) Co., Ltd. | Diarylowy związek makrocykliczny i kompozycja farmaceutyczna oraz ich zastosowanie |
| KR102850357B1 (ko) | 2018-10-22 | 2025-08-27 | 알루미스 인크. | Tyk2 억제제 및 이의 용도 |
| US20220177486A1 (en) * | 2019-03-11 | 2022-06-09 | Esker Therapeutics, Inc. | Tyk2 inhibitors and uses thereof |
| US12410191B2 (en) | 2019-05-21 | 2025-09-09 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Macrolide derivatives, preparation method and application thereof |
| CN114423762B (zh) * | 2019-09-30 | 2024-03-29 | 浙江海正药业股份有限公司 | 大环类衍生物及其制备方法和用途 |
| US20250262216A1 (en) * | 2020-03-02 | 2025-08-21 | Turning Point Therapeutics, Inc. | Therapeutic uses of macrocyclic compounds |
| WO2021244609A1 (zh) * | 2020-06-04 | 2021-12-09 | 成都倍特药业股份有限公司 | 具有大环结构的化合物及其用途 |
| CN111620881B (zh) * | 2020-07-08 | 2023-03-31 | 浙江合聚生物医药有限公司 | 拉罗替尼衍生物及其制备方法和应用 |
| CN116635076A (zh) * | 2020-12-17 | 2023-08-22 | 荣山医药股份有限公司 | 大环化合物及其用途 |
| CN114685532A (zh) * | 2020-12-31 | 2022-07-01 | 正大天晴药业集团股份有限公司 | 大环类化合物及其医药用途 |
| US20240132517A1 (en) * | 2021-02-10 | 2024-04-25 | Goharmony Therapeutics (Shenzhen) Co., Ltd. | Macrocyclic compound, pharmaceutical composition, and use thereof |
| WO2022246092A1 (en) * | 2021-05-21 | 2022-11-24 | Blossomhill Therapeutics, Inc. | Macrocyclic compounds for treating disease |
| CN116063326B (zh) * | 2021-11-02 | 2025-08-05 | 赛诺哈勃药业（成都）有限公司 | 作为蛋白激酶调节剂的含氨基大环化合物 |
| US12168640B2 (en) | 2021-11-16 | 2024-12-17 | ProDeg, LLC | USP9X inhibitors |
| CA3237744A1 (en) * | 2021-11-16 | 2023-05-25 | Richard Martinelli | Usp9x inhibitors |
| KR20240128987A (ko) | 2021-12-30 | 2024-08-27 | 바이오메아 퓨전, 인크. | Flt3의 억제제로서의 피라진 화합물 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0690843T3 (da) | 1993-03-25 | 2000-11-13 | Upjohn Co | Fornyl- eller cyanosubstituerede indolderivater med dopaninerg aktivitet |
| IL111850A (en) | 1993-12-07 | 2002-11-10 | Lilly Co Eli | Cyclic 3,4-bis (3-indolyl) maleimide protein kinase c inhibitors, their preparation and pharmaceutical composition containing them |
| GB9800569D0 (en) * | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| US7115651B2 (en) | 2000-08-25 | 2006-10-03 | Sloan-Kettering Institute For Cancer Research | Macrocycles and uses thereof |
| MXPA03005139A (es) | 2000-12-08 | 2004-01-29 | Ortho Mcneil Pharm Inc | Compuestos macroheterociclicos utiles como inhibidores de cinasa. |
| MX2011002470A (es) | 2008-09-08 | 2011-04-05 | Merck Patent Gmbh | Pirimidinas macrociclicas como inhibidores de aurora cinasa. |
| PT2350075E (pt) | 2008-09-22 | 2014-06-09 | Array Biopharma Inc | Compostos imidazo[1,2b]piridazina substituídos como inibidores da trk cinase |
| WO2010048314A1 (en) | 2008-10-22 | 2010-04-29 | Array Biopharma Inc. | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS |
| WO2010051549A1 (en) | 2008-10-31 | 2010-05-06 | Genentech, Inc. | Pyrazolopyrimidine jak inhibitor compounds and methods |
| US8497270B2 (en) | 2009-10-13 | 2013-07-30 | Elanco Animal Health Ireland Limited | Macrocyclic integrase inhibitors |
| SA111320200B1 (ar) | 2010-02-17 | 2014-02-16 | ديبيوفارم اس ايه | مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة |
| PL3205654T3 (pl) | 2010-05-20 | 2019-08-30 | Array Biopharma, Inc. | Związki makrocykliczne jako inhibitory kinazy TRK |
| UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
| EP2508607A1 (en) | 2011-04-07 | 2012-10-10 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicament for liver regeneration and for treatment of liver failure |
| CN102933765B (zh) | 2011-06-10 | 2014-03-26 | 曼泰克株式会社 | 污染防止剂组合物 |
| WO2013001310A1 (en) | 2011-06-30 | 2013-01-03 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Macrocyclic compounds and their use as cdk8 inhibitors |
| AU2012299223A1 (en) | 2011-08-19 | 2014-02-27 | Merck Sharp & Dohme Corp. | Process and intermediates for preparing macrolactams |
| BR112014007622A2 (pt) | 2011-09-30 | 2017-04-04 | Oncodesign Sa | inibidores de flt3 cinase macrocíclicos |
| PT2822953T (pt) | 2012-03-06 | 2017-04-06 | Pfizer | Derivados macrocíclicos para o tratamento de doenças proliferativas |
| PT2834243T (pt) | 2012-03-09 | 2018-08-01 | Lexicon Pharmaceuticals Inc | Compostos à base de pirazolo[1,5-a]pirimidina, composições que os compreendem e métodos para a sua utilização |
| JP6418949B2 (ja) | 2012-03-09 | 2018-11-07 | レクシコン ファーマシューティカルズ インコーポレイテッド | イミダゾ［１，２−ｂ］ピリダジン系化合物、それを含む組成物、及びそれらを使用する方法 |
| GB201205669D0 (en) | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
| WO2015073267A1 (en) | 2013-11-15 | 2015-05-21 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| EA201892241A1 (ru) * | 2014-01-24 | 2019-02-28 | ТиПи ТЕРАПЬЮТИКС, ИНК. | Диарильные макроциклы в качестве модуляторов протеинкиназ |
| TWI736134B (zh) * | 2014-09-11 | 2021-08-11 | 美商特普醫葯公司 | 作為蛋白質激酶之調節劑的二芳基巨環 |
| CA2989327A1 (en) | 2015-07-02 | 2017-01-05 | Tp Therapeutics, Inc. | Chiral diaryl macrocycles as modulators of protein kinases |
| BR112018000297A2 (pt) * | 2015-07-06 | 2018-09-04 | Tp Therapeutics Inc | polimorfo de macrociclo de diarila |
| PT3733187T (pt) * | 2015-07-21 | 2024-11-08 | Turning Point Therapeutics Inc | Macrociclo de diarilo quiral e utilização do mesmo no tratamento do cancro |
| EP3371190B1 (en) * | 2015-11-06 | 2022-03-30 | Incyte Corporation | Heterocyclic compounds as pi3k-gamma inhibitors |
| CA3031100A1 (en) | 2016-07-28 | 2018-02-01 | Tp Therapeutics, Inc. | Macrocycle kinase inhibitors |
| RU2764523C2 (ru) * | 2016-10-28 | 2022-01-18 | Чиа Тай Тянцин Фармасьютикал Груп Ко., Лтд. | Соединение аминопиразолопиримидина, используемое в качестве ингибитора тирозинкиназного рецептора нейротрофического фактора |
| TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| MY201925A (en) * | 2017-07-28 | 2024-03-23 | Turning Point Therapeutics Inc | Macrocyclic compounds and uses thereof |
| WO2019120267A1 (zh) | 2017-12-22 | 2019-06-27 | 成都先导药物开发股份有限公司 | 一种咪唑并[1,2-b]哒嗪大环类激酶抑制剂 |
| ES2925578T3 (es) | 2018-04-18 | 2022-10-18 | Hitgen Inc | Inhibidor de cinasas macrocíclico |
-
2018
- 2018-07-26 MY MYPI2019007871A patent/MY201925A/en unknown
- 2018-07-26 JP JP2020504026A patent/JP7224334B2/ja active Active
- 2018-07-26 BR BR112020001695-0A patent/BR112020001695A2/pt not_active Application Discontinuation
- 2018-07-26 ES ES18838274T patent/ES2986593T3/es active Active
- 2018-07-26 SG SG11202000356VA patent/SG11202000356VA/en unknown
- 2018-07-26 LT LTEPPCT/US2018/043817T patent/LT3658148T/lt unknown
- 2018-07-26 EP EP18838274.1A patent/EP3658148B1/en active Active
- 2018-07-26 US US16/634,289 patent/US11286264B2/en active Active
- 2018-07-26 DK DK18838274.1T patent/DK3658148T3/da active
- 2018-07-26 AU AU2018306328A patent/AU2018306328B2/en not_active Ceased
- 2018-07-26 PT PT188382741T patent/PT3658148T/pt unknown
- 2018-07-26 UA UAA202000271A patent/UA126158C2/uk unknown
- 2018-07-26 FI FIEP18838274.1T patent/FI3658148T3/fi active
- 2018-07-26 HR HRP20241197TT patent/HRP20241197T1/hr unknown
- 2018-07-26 RS RS20240945A patent/RS65884B1/sr unknown
- 2018-07-26 SI SI201831143T patent/SI3658148T1/sl unknown
- 2018-07-26 CA CA3069232A patent/CA3069232A1/en active Pending
- 2018-07-26 PE PE2020000127A patent/PE20200700A1/es unknown
- 2018-07-26 PL PL18838274.1T patent/PL3658148T3/pl unknown
- 2018-07-26 WO PCT/US2018/043817 patent/WO2019023417A1/en not_active Ceased
- 2018-07-26 CN CN201880049611.1A patent/CN111182903A/zh active Pending
- 2018-07-26 IL IL271964A patent/IL271964B2/en unknown
- 2018-07-26 SM SM20240343T patent/SMT202400343T1/it unknown
- 2018-07-26 KR KR1020207000229A patent/KR102645316B1/ko active Active
- 2018-07-27 TW TW107126181A patent/TWI818917B/zh active
-
2020
- 2020-01-02 PH PH12020500033A patent/PH12020500033A1/en unknown
- 2020-01-20 CL CL2020000169A patent/CL2020000169A1/es unknown
- 2020-01-21 CO CONC2020/0000633A patent/CO2020000633A2/es unknown
- 2020-01-21 SA SA520411108A patent/SA520411108B1/ar unknown
-
2021
- 2021-03-25 US US17/213,093 patent/US11155563B2/en active Active
-
2022
- 2022-02-22 US US17/676,942 patent/US11981684B2/en active Active
-
2023
- 2023-02-07 JP JP2023016586A patent/JP7554300B2/ja active Active
-
2024
- 2024-04-09 US US18/630,760 patent/US20240391935A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20200700A1 (es) | Compuestos macrociclicos y usos de los mismos | |
| PE20181491A1 (es) | Nuevos derivados biciclicos, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| PE20200937A1 (es) | Compuestos macrociclicos para tratar enfermedades | |
| PE20212303A1 (es) | Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer | |
| PE20180949A1 (es) | Nuevos derivados hidroxiacido, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| CL2016002348A1 (es) | Agonistas del receptor muscarínico | |
| CL2020003260A1 (es) | Compuestos de naftiridinona sustituidos útiles como activadores de células t | |
| CL2019000512A1 (es) | Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica. | |
| CU20170073A7 (es) | Compuestos de indazol sustituidos y compuestos intermediarios para la preparación de los mismos | |
| PE20181145A1 (es) | Compuestos de piridina | |
| PE20240775A1 (es) | Compuestos antivirales | |
| PE20181298A1 (es) | Inhibidores de bromodominio bivalentes y usos de los mismos | |
| CL2022001710A1 (es) | Derivados bicíclicos sustituidos de piperidina útiles como activadores de células t | |
| MX2020011469A (es) | Derivados de 6,7-dihidro-5h-benzo[7]anuleno como moduladores de receptores de estrogenos. | |
| PE20220567A1 (es) | Nuevos derivados piperidinilo, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| AR109315A1 (es) | Composiciones farmacéuticas que contienen derivados de piridona policíclica sustituida y profármaco de las mismas | |
| PE20190326A1 (es) | Isoquinolin-3-il-carboxamidas y preparacion y uso de las mismas | |
| PE20190509A1 (es) | 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas | |
| PE20200292A1 (es) | Compuestos de heteroarilo biciclicos 6-6 fusionados y su uso como inhibidores de lats | |
| PE20161405A1 (es) | Analogos de cortistatina y sintesis y usos de los mismos | |
| ES2770058T3 (es) | Compuestos y composiciones destinados a modular las actividades de quinasa de EGFR mutante | |
| MX379530B (es) | Compuestos agonistas del receptor muscarínico m4. | |
| AR059957A1 (es) | DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER. | |
| AR072016A1 (es) | Derivados de isoxazol que funcionan como potenciadores de los receptores de glutamato | |
| PE20110196A1 (es) | 5-alquinil-pirimidinas |